dm+d
Unassigned
New Medicines
Moderate-to-severe alopecia areata
Information
New molecular entity
Pfizer
Pfizer
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Janus kinase-3 (JAK3) inhibitor
In the UK, alopecia areata is estimated to affect about 15 in 10,000 people. [1]
Moderate-to-severe alopecia areata
Oral
Further information
Yes